Results from in vivo studies will provide an opportunity to develop structure-activity relationship (SAR)-based CMLD-2 inhibitors and a strong rationale to develop HuR-targeted small molecule therapeutics for treating lung cancer and other solid tumors. This evidence concerns the gene ELAVL1 and lung cancer.